Research on IL27RA in breast cancer highlights the role of immune checkpoint signaling in tumor progression, suggesting that ligand-engineered RNVs could concurrently deliver therapeutic agents and modulate inhibitory pathways [57]. Here, IL27RA is linked to breast carcinoma.